Conference Call with Dr. Lal Pathlabs Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Services company Dr. Lal Pathlabs announced Q4FY23 & FY23 results: Dr. Lal PathLabs records revenue of Rs 491 crore in Q4FY23 Non-Covid Revenue increased by 14.4% in Q4FY23 & 15.5% in FY23 Normalised EBITDA margin (after adjustment for stock-based compensation, CSR & exceptional expenses) for Q4FY23 is 26.6% & 26.2% for FY23 The normalised PAT margin for Q4FY23 is 15.5% and 14.7% for FY23 Result PDF
Conference Call with Dr. Lal Pathlabs Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript.
Healthcare service firm Dr. Lal Pathlabs announced Q3FY23 results: Consolidated Q3FY23 vs Q3FY22: Non-Covid revenue increased by 9.1% in Q3FY23 to Rs 478 crore vs Rs 438 crore in Q3FY22. Total revenue declined by 1.5% in Q3FY23 to Rs 489 crore vs Rs 497 crore in Q3FY22. Covid and Allied contributed 2% to revenue in Q3FY23, and 12% in Q3FY22. Normalised EBITDA (after adjustment for stock-based compensation, CSR) for Q3FY23 is at Rs 122 crore (margins 24.9%) vs Rs 119 crore in the same quarter last year. Normalised PBT at Rs 89 crore, margins 18.2% vs Rs 90 crore in Q3 last year. Normalised PAT at Rs 66 crore, margins 13.5% vs Rs 66 crore in Q3 last year. Result PDF